Unique today
As of 10/3/2025 04:00 pm
- 52 weeks
- $ 4.82
▼
60.70 dollars
- The target price
- 68.42 dollars
In one of the most incredible moves this year, the shares in the field of biotechnology UNIQURE Nasdak: quer It increased by 284 % on September 24. This came at a time when the company released great clinical results for its development medicine, AMT-130.
With such a huge height, UNIQURE transforms the heads of the Wall Street analysts. Most of them still see up, which implicitly means a highly dangerous and highly rewarding opportunity for investors.
So, what exactly what Unique do, and why are the markets very excited about this arrow? In addition, what are the UNIQURE prospects that suffer from more appreciation? Let’s dive into these questions below.
Huntington’s results send Quire to the moon
UNIQURE develops genetics, as Huntington’s disease was the most focus of its concentration instantly. This is where its treatment comes, AMT-130, on September 24, the company provided the data of the Food and Drug Administration experience from the first/second stage that detonated analysts.
In 36 months, AMT-130 achieved the basic end points, which show a 75 % statistically slow The development of Huntington’s disease among patients at a high dose. The researchers measured this using the Cuhdrs compared to historical data. The compound provides a comprehensive vision of the development of the disease, and the combination of functional, cognitive and motor tests.
The experiment also faced the secondary end point, indicating a 60 % slowdown in the development of the disease based on the overall functional ability (TFC). TFC measures the quality of the patient from performing daily tasks without assistance. Within medical research, the end points that measure the quality of patients of patients are particularly desirable. It provides clear evidence that patients will actually be better and that the cost of treatment deserves it. Strong results and the nature of the data well for the ATT-1330 capacity to obtain the approval of the Food and Drug Administration. Approval will be translated into large revenues for UNIQURE and support more gains in the price of its share.
Analysts offer glowing reviews of the AMT-130 data, goals indicate the upper direction
Unique stock forecast today
68.42 dollars
24.58 % upModerate purchase
Based on 12 analyst classifications
| The current price | 54.92 dollars |
|---|---|
| High expectations | 95.00 dollars |
| Average expectations | 68.42 dollars |
| Low expectations | $ 24.00 |
Expected details Unique
In the version of the data version, analysts noticed that the AMT-130 results were “amazing” and “very encouraging”. This highlights how the AMT-130 data has greatly exceeded expectations. With the results, the AMT-130 has a strong opportunity to become the first treatment for a disease modification for Hyington. This may be a golden ticket for the company, as the AMT-130 works to slow the disease instead of simply relieving symptoms.
In general, the price of the Marketbeat consensus on Uniquure is slightly more than $ 67. However, with the exception of the HC Wainwright’s goal of $ 52, which has not been updated since 2024, the average has been moving to $ 73. This goal indicates that stocks may rise by 25 %, which is a significant improvement in consensus.
The slightest updated goal comes from $ 56 from Goldman Sachs. Although it is the most expected expectation, it still means about 4 % on the downside in the stocks. On the other hand, the extreme upward goals of $ 95 come from both Guggenheim and UBS. Achieving this level will require additional profit in shares of about 63 %.
The Amt-130 Road seems to be promising approval, but the risk of biotechnology is still looming on the horizon
To achieve this bullish goal, UNIQURE likely you need to obtain FDA approval for AMT-130. UNIQURE plans to provide drugs for approval in the first quarter of 2026. In the second quarter of 2025, the company obtained an organizational alignment with the Food and Drug Administration. The FDA (FDA) said it will use data from the first/second stage experience to evaluate the accelerating approval of AMT-130. This mainly exceeded the need to try the third stage, which led to a somewhat disposal of the ATT-130 course for approval.
Analysts seem bullish on the ATT-130’s ability to obtain the approval of the Food and Drug Administration. Leerink Partners says current results support approval, which creates limited organizational risks about Unique. Although the target price has decreased for 12 months, Goldman Sachs He sees a possibility of 90 % From AMT-130 up to the peak of annual sales amounting to $ 2.5 billion. Currently, the average price ratio forward to the PES (P/S) in the United States is the average price to the PIS (P/S) is around 5X. Thus, if AMT-130 realizes the Goldman Peak sales expectations, there may be a lot of field in favor of UNIQURE to exceed the maximum current market of $ 4.3 billion in the long run.
In general, it seems that UNIQURE has a great opportunity to obtain FDA approval of AMT-130. This will be a major stimulus for higher ride. However, biotechnology stocks are some of the most dangerous in the market, and none of these analysts have a crystal ball. If the AMT-130, the arrow can return a large amount of the gain it has achieved. The Congress Budget Office estimates that the Food and Drug Administration Only 12 % of drug candidates agree. This highlights the sharp possibilities that UNIQURE and the risks of biotechnology industry.
UNIQURE NV (Qure) Prices (Qure) for Saturday, 4 October, 2025
Before you think about Unique, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before wiping the broader market … and it was not unique in the list.
While Unique currently has a moderate purchase classification between analysts, analysts from senior exporters believe that these five stocks buy better.
Show the five stocks here
Marketbeat analysts just released the best five short plays in October 2025. Learn the stocks that have the most short interest and how to trade. Enter your email address to know the companies that have set the list.
